Latest Opthea (Asx:Opt) News

Opthea Limited has announced a strategic pivot to develop OPT-302 for Lymphangioleiomyomatosis (LAM), a rare lung disease affecting women, aiming for ASX reinstatement in 2026. The company leverages strong intellectual property and cash reserves to pursue orphan drug designation and clinical development.

Opthea has significantly reduced its operating costs and settled a key financial liability, positioning itself for a strategic review aimed at unlocking shareholder value.

Opthea Limited has received a substantial A$10.8 million R&D tax incentive from the Australian government, reinforcing its commitment to advancing its novel drug candidate sozinibercept. This funding milestone underscores the company’s strategic focus on innovation and fiscal discipline.

S&P Dow Jones Indices has announced its September 2025 quarterly rebalance, reshuffling key constituents across multiple S&P/ASX indices effective September 22. The changes highlight shifting market dynamics with notable additions and removals in sectors ranging from technology to resources.

Opthea Limited reported a 26% reduction in net loss for FY2025 despite discontinuing its wet AMD drug after failed Phase III trials. The company settled its Development Funding Agreement with investors, securing liquidity and planning a strategic pivot.

Opthea Limited has terminated its sozinibercept wet AMD program following Phase 3 trial failures and settled a major funding agreement, setting the stage for a strategic reset.

Opthea has successfully settled its Development Funding Agreement, avoiding a potential $680 million liability and securing $20 million in cash. Leadership changes include the CEO and CFO stepping down, with the Chairman assuming CEO duties.

Opthea has discontinued its sozinibercept program after Phase 3 trial failures, leading to drastic staff cuts and a sharp decline in cash reserves amid ongoing funding negotiations.

Opthea Limited faces a pivotal moment as four board members resign following disappointing Phase 3 trial results and a major workforce reduction. The company’s future hinges on ongoing funding negotiations amid trading suspensions.

Opthea Limited has discontinued its wet AMD development program following Phase III trial failures, slashing its workforce by 65% amid ongoing financial uncertainty and negotiations with investors.

Opthea has completed the final patient visit in its pivotal COAST Phase 3 trial evaluating sozinibercept combined with aflibercept for wet AMD, with topline results expected early Q2 2025.

Opthea Limited reports steady progress in its Phase 3 trials for sozinibercept, a novel treatment for wet AMD, supported by a strong cash position and a recent R&D tax incentive.